血型分型市场（按产品类型、技术、最终用户和应用）—全球预测 2025-2032

预计到 2032 年血型鑑定市场规模将成长至 67.6 亿美元，复合年增长率为 8.05%。

主要市场统计数据
基准年2024年	36.3亿美元
预计2025年	39.3亿美元
预测年份：2032年	67.6亿美元
复合年增长率（%）	8.05%

对不断发展的血型状况的权威介绍，强调临床安全优先事项、技术转型以及实验室和输血服务的运作要求

血型鑑定领域处于临床安全、实验室效率和技术创新的交汇点。自动化、试剂化学和分子平台的进步正在逐步将常规工作流程从手动、劳动密集型任务转变为整合系统，从而减少人为错误并加快週转时间。同时，对输血安全和精准医疗的日益重视，也使得强大的血型鑑定解决方案在血库、临床实验室和医院诊断部门的战略重要性日益凸显。

在此背景下，相关人员正在应对复杂的遗留基础设施、新兴分子诊断技术和不断变化的监管预期。与实验室资讯系统的互通性以及对抗血清和试剂红血球的有效供应链管理仍然是营运的优先事项。此外，人口趋势、周产期护理需求以及对感染疾病增强的警觉性等因素，持续推动先进筛检和输血前检测通讯协定的采用。随着实验室和血液服务机构重新评估其套件，在整合能够显着改善患者安全性的技术的同时，平衡成本、可靠性和合规性至关重要。

全面回顾再形成血型的重大变革，包括自动化、分子整合、试剂进步和可互通的测试系统

近年来，一场变革性的转变正在重新定义血型分型的执行和管理方式。仪器平台的自动化已从理想目标转变为大批量生产中心的实际需求，从而减少了人工干预并实现了结果的一致性。同时，聚合酵素链锁反应等分子技术已将血型分型的范围扩展到血清学之外，为复杂的抗原谱和产前筛检应用提供了更高的特异性。

此外，试剂创新促进了抗血清製剂和经验证的筛检细胞的开发，从而提高了检测稳定性并减少了可疑结果的发生。与实验室资讯系统的整合简化了报告、可追溯性和合规性工作流程，使其逐渐成为预期功能，而非差异化因素。这种转变促使人们更加关注仪器支援服务和生命週期管理，以确保执行时间和校准标准符合临床吞吐量需求。总而言之，这些发展正在创造一个更具弹性、互通性且诊断更精细的血型分析环境，既支持常规输血实践，也支持专门的临床场景。

深入分析近期美国关税调整如何影响整个血型检测供应链的筹资策略、供应商多样化和库存弹性

关税变化和贸易政策调整将对实验室和血液服务筹资策略、供应链弹性和成本结构产生即时和持续的影响。美国近期的关税行动促使采购部门和采购负责人重新评估其进口设备、试剂和耗材的采购途径。这些调整促使供应商更积极地多元化，许多组织正在寻求替代供应商、区域分销商或国内製造合作伙伴，以减轻进口相关成本波动的风险。

此外，关税环境促使库存管理加强，并与供应商签订了更严格的合约条款，以保持服务的连续性。对于一些相关人员，跨境物流日益复杂，促使他们投资长期供应协议，并与主要供应商进行联合预测，以防止运输延误和海关相关的中断。同时，临床使用的法规合规性和合格要求限制了关键试剂和系统的快速替换，因此需要精心安排过渡和检验方案。因此，采购团队必须在应对力与对经过检验、符合临床要求的产品的严格需求之间取得平衡。

基于细分的关键洞察揭示了产品类型、技术、最终用户需求和临床应用将如何决定血型检测的采购和部署策略

细分洞察揭示了临床需求、技术能力和服务期望在哪些方面交汇，从而影响采购和部署决策。实验室会根据产品类型评估自动血型仪和凝胶卡分析仪等设备的通量及其与现有工作流程的兼容性，而抗血清试剂、试剂红血球和筛检细胞等试剂组合则会根据稳定性、特异性和监管文件进行评判。互补软体和服务（包括实验室资讯系统整合、支援和维护）对价值主张的提案日益凸显，因为它们能够简化报告流程并实现长期业务连续性。

在考虑技术时，组织会权衡流式细胞技术的高灵敏度抗原检测、用于常规分型的凝胶离心的稳健性、微孔盘凝集的高通量筛检能力，以及用于基因分型的分子即时PCRPCR 平台）。技术的选择取决于临床复杂性、所需的通量以及产前或输血医学病例所需的分子分辨率水平。最终用户细分进一步明确了采用模式：政府和私人血库优先考虑捐赠者筛检效率和冷链物流，医院独立临床实验室强调工作流程整合和周转时间，私立和公立医院优先考虑可靠的输血前检测和新生儿筛检能力。

以应用为重点的分析强调，捐赠者筛检（包括血型鑑定和传染病筛检）需要扩充性且经过验证的系统，这些系统能够在捐赠活动和集中采集设施中持续运作。新生儿筛检需要能够快速检验途径并最大程度减少假阳性的检测方法和工作流程。输血前检测强调交叉试验在时间敏感的临床环境中的可靠性和相容性。在所有领域，设备选择、试剂稳定性、技术选择和服务协议之间的相互作用决定了临床表现和长期运作的永续性。

从区域观点解释供应链弹性、监管多样性和医疗保健基础设施如何影响全球市场的血型采用模式

区域动态影响整个血型价值链的采购选择、监管导向和伙伴关係模式。在美洲，临床实验室和血液服务机构通常青睐高通量血液中心和遵循既定监管路径的整合自动化系统。这种环境支持采用成熟的血清学平台和不断发展的分子检测方法，以补充输血安全计画。同时，该地区的战略采购越来越多地考虑国内製造能力和区域分销网络，以缓解供应链摩擦。

欧洲、中东和非洲地区管理体制和基础设施水准参差不齐，既带来了机会，也带来了挑战。该地区的一些市场优先考虑高度检验的试剂系统和跨境医疗保健网路的标准化通讯协定，而其他市场则投资于可在资源受限环境中部署的可扩展技术。公共和私营相关人员的合作倡议在推广新生儿筛检和输血前工作流程的最佳实践方面发挥关键作用。

在亚太地区，人口趋势和不断扩大的医疗保健覆盖范围正在推动对集中检测服务和区域参考中心的投资增加。这推动了对可扩展至多站点运营的模组化仪器平台以及能够确保可靠配送和低温运输管理的试剂供应商的需求。在整个地区，本地支援能力、监管透明度和供应链韧性对于技术和服务的长期采用和维持仍然至关重要。

竞争动态分析突显了成熟的诊断製造商、专业试剂製造商、软体整合商和创新新参与企业在血型生态系中的作用

血型检测领域的竞争态势取决于成熟诊断设备製造商、专业试剂製造商以及敏捷软体和服务公司之间的平衡。成熟的仪器供应商凭藉着检验的平台、认证的服务网络以及与高容量血液中心和医院实验室的长期合作关係，保持优势。这些公司投资于产品生命週期管理和法规遵从性，提供将仪器与校准试剂和维护合约捆绑在一起的综合方案，以确保可预测的临床性能。

同时，专业试剂供应商和契约製造製造商正致力于提供能够提高试剂稳定性、降低批次间差异并促进临床实验室验证工作的产品。软体供应商和系统整合在实现实验室资讯系统连接、电子报告和品管监控方面变得越来越重要。新兴企业公司正在透过新型分子检测、数位PCR工作流程和云端分析进行创新，而成熟公司则正在加速其研发和伙伴关係策略。采购主管必须综合考虑临床检验数据、服务能力、供应连续性保证以及支援与现有实验室IT生态系统整合的能力来评估潜在供应商。

为产业领导者提供切实可行的建议，重点在于互通性、供应商多样化、预测性维护、平衡分子整合和相关人员协作

产业领导者应采取一系列切实可行的优先事项，使临床需求与营运现实和策略成长目标一致。首先，优先投资可互通的系统，以促进仪器平台与实验室资讯系统之间的无缝集成，减少人工抄录错误，并加快结果报告速度。其次，制定强有力的供应商多元化策略，包括经审查的区域经销商和替代试剂供应商，以缓解供应链中断和关税相关的不确定性，同时保持合规性和验证的严谨性。

第三，扩大服务和维护合同，在可行的情况下纳入预测性维护能力和远距离诊断，最大限度地延长设备运作，减少被动干预的需求。第四，将分子基因分型方法纳入复杂病例和产前筛检的工作流程，同时在常规、高容量场景中保留血清学方法，优化成本效益和诊断解析度。第五，加强与临床相关人员和监管机构的合作，简化新检测方法的验证途径，并确保程序变更符合病人安全标准。透过采取这些措施，各组织可以提高韧性，促进技术创新的应用，并维持输血安全和实验室性能的高标准。

清楚概述了严格的相关人员主导的调查方法，该方法结合了定性专家参与、技术基础评估和供应链情境分析来检验见解

这些见解背后的调查方法依赖于一种结构化方法，该方法结合了原始研究和二手资料，以确保分析的严谨性和实践相关性。与实验室主任、采购经理、血库负责人和临床病理学家的交流，提供了关于仪器性能、试剂可靠性和​​服务期望的现场观点。这些定性资讯与平台功能的技术评估、监管文件审查以及技术采用趋势分析相结合，从而全面整体情况营运重点和临床需求。

此外，我们还进行了产品和工作流程评估，以比较血清学和分子检测方法的功能，并专注于互通性、通量和验证要求。透过相关人员访谈和情境分析评估了供应链和采购流程，以评估应对关税和物流变化的韧性策略。在整个过程中，我们专注于跨多个资料来源和相关人员类型的三角测量结果，以最大程度地减少偏差，并确保为临床和机构决策者提供切实可行的建议。

结论证实，策略整合、供应链弹性和协作创新对于提高输血安全和实验室绩效至关重要

总而言之，血型分型领域正在经历一场务实的变革，其特点是自动化程度不断提高、分子检测能力不断扩展，并更加重视供应链的韧性和互通性。输血安全、新生儿筛检和可靠的捐血者筛检等临床需求持续推动着对经过临床检验、运作永续且以强大服务框架为基础的解决方案的需求。随着实验室和血液服务机构应对不断变化的资费、监管复杂性和技术选择，那些优先考虑检验、供应商可靠性和自适应采购的组织将最有能力提供一致、以患者为中心的结果。

展望未来，诊断製造商、试剂供应商、软体整合商和临床相关人员之间的持续合作对于将创新转化为日常实践至关重要。透过将投资与临床工作流程的实际情况和监管期望相结合，相关人员可以确保技术进步不仅能提高诊断准确性，还能增强输血操作及相关临床项目的效率和安全性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 采用基于次世代定序的血型基因分型平台来加强输血安全性和相容性测试
• 在紧急和严重监护环境中整合人工智慧分析的照护现场血型检测设备的成长
• 增加对基于微阵列的高通量血液抗原筛检技术的投资，以实现最佳的供体-受体匹配
• 智慧型手机血凝试验的出现，可用于偏远医疗机构的分散血型测定
• 监管部门推广使用无细胞 DNA 检测平台进行非侵入性胎儿 RhD 基因分型，以降低同种免疫风险
• 整合区块链技术，实现跨医院和输血网路的安全、可追溯的血型资料管理
• 高容量临床实验室采用完全整合的血型分析仪实现从样本到结果的自动化

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 血型分型市场（依产品类型）

• 装置
  • 自动血型测定装置
  • 凝胶卡分析仪
• 试剂
  • 抗血清试剂
  • 试剂红血球
  • 筛检细胞
• 软体和服务
  • LIS 集成
  • 支援和维护

9. 血型分型市场（依技术）

• 流式细胞技术
• 凝胶离心
• 微孔盘凝集反应
• PCR
  • 数位PCR
  • 即时PCR

第 10 章 血型分型市场（依最终使用者）

• 血库
  • 政府血库
  • 私人血库
• 临床实验室
  • 医院附设检查室
  • 独立研究机构
• 医院和诊断中心
  • 私立医院
  • 公立医院

第11章血型分型市场的应用

• 捐赠者筛检
  • 血型
  • 传染病筛检
• 新生儿筛检
• 输血前检测

第十二章 血型分型市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 血型分型市场（依人群）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 血型分型市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Ortho Clinical Diagnostics, Inc.
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Grifols, SA
  • Bio-Rad Laboratories, Inc.
  • Immucor, Inc.
  • Sysmex Corporation
  • BioMerieux SA
  • Quotient Limited
  • Fujirebio Holdings, Inc.

The Blood Group Typing Market is projected to grow by USD 6.76 billion at a CAGR of 8.05% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 3.63 billion
Estimated Year [2025]	USD 3.93 billion
Forecast Year [2032]	USD 6.76 billion
CAGR (%)	8.05%

An authoritative introduction to the evolving blood group typing landscape highlighting clinical safety priorities, technological transitions, and operational imperatives within laboratory and transfusion services

The landscape of blood group typing sits at the intersection of clinical safety, laboratory efficiency, and technological innovation. Advancements in automation, reagent chemistry, and molecular platforms have progressively shifted routine workflows away from manual, labor-intensive tasks toward integrated systems that reduce human error and accelerate turnaround times. In parallel, rising emphasis on transfusion safety and precision medicine has elevated the strategic importance of robust typing solutions across blood banks, clinical laboratories, and hospital diagnostic units.

Against this backdrop, stakeholders are navigating a complex mix of legacy infrastructure, emerging molecular diagnostics, and evolving regulatory expectations. Interoperability with laboratory information systems and the need for effective supply chain management for antisera and reagent red blood cells remain operational priorities. Furthermore, the confluence of demographic trends, perinatal care imperatives, and heightened infectious disease vigilance continues to drive adoption of advanced screening and pretransfusion testing protocols. As laboratories and blood services reassess their toolkits, the imperative is to balance cost, reliability, and regulatory compliance while embracing technologies that deliver measurable improvements in patient safety.

A comprehensive review of the major transformative shifts reshaping blood group typing including automation, molecular integration, reagent advancements, and interoperable laboratory systems

Recent years have seen transformative shifts that are redefining how blood group typing is performed and managed. Automation in instrument platforms has transitioned from an aspirational goal to a practical necessity for high-volume centers, enabling consistent results with reduced manual intervention. Concurrently, molecular techniques such as polymerase chain reaction methodologies are expanding the scope of typing beyond serology, offering higher specificity for complex antigen profiles and prenatal screening applications.

In addition, reagent innovation-spanning antisera formulations and validated screening cells-has enhanced assay stability and reduced incidence of equivocal results. Integration with laboratory information systems has matured into an expected capability rather than a differentiator, streamlining reporting, traceability, and compliance workflows. These shifts are accompanied by an increasing emphasis on support services and lifecycle management for instruments, ensuring that uptime and calibration standards meet clinical throughput demands. Taken together, these developments are producing a more resilient, interoperable, and diagnostically sophisticated blood typing environment that supports both routine transfusion operations and specialized clinical scenarios.

A detailed analysis of how recent United States tariff adjustments have influenced procurement strategies, supplier diversification, and inventory resilience across blood group typing supply chains

Tariff changes and trade policy adjustments can have immediate and downstream effects on procurement strategies, supply chain resilience, and cost structures for laboratories and blood services. In the context of recent tariff movements in the United States, purchasing departments and procurement officers have been prompted to re-evaluate sourcing routes for imported instruments, reagents, and consumables. These adjustments have fostered more deliberate supplier diversification, with many organizations seeking alternative vendors, regional distributors, or domestic manufacturing partners to mitigate exposure to import-related cost volatility.

Moreover, the tariff environment has incentivized tighter inventory management and more rigorous vendor contract terms to preserve service continuity. For some stakeholders, the increased complexity in cross-border logistics led to investment in longer-term supply agreements and collaborative forecasting with key suppliers to protect against shipment delays and customs-related disruptions. At the same time, regulatory conformity and qualification requirements for clinical use have constrained rapid substitution of critical reagents or systems, necessitating carefully sequenced transitions and validation protocols. Consequently, procurement teams must balance responsiveness to trade shifts with the uncompromising need for validated, clinically compliant products.

Key segmentation-driven insights that illuminate how product type, technology, end-user demands, and clinical applications collectively dictate procurement and deployment strategies in blood group typing

Segmentation insights reveal where clinical demand, technological capabilities, and service expectations converge to shape purchasing and deployment decisions. Based on product type, laboratories evaluate instruments such as automated blood typers and gel card analyzers for throughput and compatibility with existing workflows, while reagent portfolios covering antisera reagents, reagent red blood cells, and screening cells are judged on stability, specificity, and regulatory documentation. Complementary software and services, including laboratory information system integration and support and maintenance offerings, are increasingly central to value propositions because they enable streamlined reporting and long-term operational continuity.

When considering technology, organizations weigh the trade-offs between flow cytometry's high-sensitivity antigen detection, gel centrifugation's robustness for routine typing, microplate agglutination's high-throughput screening capacity, and molecular PCR approaches that encompass both digital PCR and real-time PCR platforms for genotyping. The choice of technology is driven by clinical complexity, required throughput, and the level of molecular resolution needed for prenatal or transfusion medicine cases. End-user segmentation further clarifies adoption patterns: government and private blood banks prioritize donor screening efficiency and cold-chain aligned reagent logistics; hospital-based and independent clinical laboratories emphasize workflow integration and turnaround times; and private and public hospitals focus on reliable pretransfusion testing and newborn screening capabilities.

Application-focused analysis underscores that donor screening, including blood typing and infectious disease screening, demands scalable, validated systems that can operate consistently at donor drives and centralized collection sites. Newborn screening requires assays and workflows that minimize false positives while enabling rapid confirmatory pathways. Pretransfusion testing emphasizes crossmatch reliability and compatibility determination under time-constrained clinical settings. Across all segments, the interplay between instrument selection, reagent robustness, technology choice, and service agreements determines both clinical performance and long-term operational sustainability.

Regional perspectives that explain how supply chain resilience, regulatory diversity, and healthcare infrastructure are shaping adoption patterns for blood group typing across global markets

Regional dynamics influence procurement choices, regulatory navigation, and partnership models across the entire blood group typing value chain. In the Americas, clinical laboratories and blood services often favor integrated automation that aligns with high-throughput blood centers and well-established regulatory pathways; this environment supports adoption of both mature serological platforms and evolving molecular methods that complement transfusion safety programs. Meanwhile, strategic purchasing in the region is increasingly informed by considerations of domestic manufacturing capability and regional distribution networks to reduce supply chain friction.

In Europe, the Middle East, and Africa region, heterogeneous regulatory regimes and variable infrastructure levels create both opportunities and challenges. Some markets within this region prioritize highly validated reagent systems and standardized protocols for transnational healthcare networks, while others are investing in scalable technologies that can be deployed in resource-constrained settings. Interoperability and compliance with regional standards frequently drive supplier selection, and collaborative initiatives across public and private stakeholders play a key role in disseminating best practices for newborn screening and pretransfusion workflows.

Within the Asia-Pacific region, demographic trends and expanding healthcare coverage are prompting increased investment in centralized laboratory services and regional reference centers. This has elevated demand for modular instrument platforms that can be scaled across multi-site operations, as well as for reagent suppliers that can ensure reliable distribution and cold-chain management. Across all regions, local support capabilities, regulatory clarity, and supply chain resilience remain pivotal in determining how technologies and services are adopted and sustained over time.

An analysis of competitive dynamics highlighting the roles of established diagnostic manufacturers, reagent specialists, software integrators, and innovative newcomers in the blood group typing ecosystem

Competitive dynamics in the blood group typing domain are defined by a balance between established diagnostic manufacturers, specialized reagent producers, and agile software and services firms. Established instrument vendors maintain advantage through validated platforms, certified service networks, and long-term relationships with high-volume blood centers and hospital laboratories. These players invest in product lifecycle management and regulatory compliance, offering comprehensive packages that bundle instruments with calibrated reagents and maintenance contracts to ensure predictable clinical performance.

At the same time, specialized reagent manufacturers and contract producers focus on improving reagent stability, reducing lot-to-lot variability, and providing products that ease validation efforts for clinical laboratories. Software providers and systems integrators are increasingly critical for enabling laboratory information system connectivity, electronic reporting, and quality control monitoring. Emerging companies and startups bring innovation through novel molecular assays, digital PCR workflows, or cloud-enabled analytics, prompting incumbents to accelerate their own R&D and partnership strategies. For procurement leaders, the imperative is to evaluate potential suppliers on a combination of clinical validation data, service capability, supply continuity guarantees, and the ability to support integration with existing laboratory IT ecosystems.

Actionable recommendations for industry leaders focused on interoperability, supplier diversification, predictive maintenance, balanced molecular integration, and stakeholder collaboration

Industry leaders should pursue a set of actionable priorities that reconcile clinical demands with operational realities and strategic growth objectives. First, prioritize investments in interoperable systems that facilitate seamless integration between instrument platforms and laboratory information systems to reduce manual transcription errors and accelerate result reporting. Second, develop robust supplier diversity strategies that include vetted regional distributors and alternative reagent sources to mitigate supply chain disruptions and tariff-related uncertainties while preserving compliance and validation rigor.

Third, expand service and maintenance agreements to include predictive maintenance capabilities and remote diagnostics where feasible, thereby maximizing instrument uptime and reducing the need for reactive interventions. Fourth, incorporate molecular genotyping methods into workflows for complex cases and prenatal screening while retaining serological techniques for routine, high-volume scenarios to optimize both cost-effectiveness and diagnostic resolution. Fifth, strengthen collaboration with clinical stakeholders and regulatory bodies to streamline validation pathways for new assays and to ensure that procedural changes are aligned with patient safety standards. By adopting these measures, organizations can improve resilience, enable innovation adoption, and sustain high standards of transfusion safety and laboratory performance.

A clear overview of the rigorous, stakeholder-driven research methodology combining qualitative expert engagement, technical platform assessments, and supply chain scenario analyses to validate insights

The research methodology underpinning these insights relies on a structured blend of primary and secondary approaches to ensure analytical rigor and practical relevance. Engagements with laboratory directors, procurement managers, blood bank leaders, and clinical pathologists provided ground-level perspectives on instrument performance, reagent reliability, and service expectations. These qualitative inputs were synthesized with technical evaluations of platform capabilities, regulatory documentation reviews, and analyses of technology adoption dynamics to create a comprehensive picture of operational priorities and clinical needs.

In addition, product and workflow assessments were conducted to compare functionality across serological and molecular techniques, with attention to interoperability, throughput, and validation requirements. Supply chain and procurement processes were examined through stakeholder interviews and scenario analysis to assess resilience strategies in the face of tariff and logistics shifts. Throughout the process, emphasis was placed on triangulating findings across multiple data sources and stakeholder types to minimize bias and ensure that recommendations remain actionable for decision-makers operating in clinical and institutional contexts.

A decisive conclusion affirming that strategic integration, supply chain resilience, and collaborative innovation are essential for advancing transfusion safety and laboratory performance

In conclusion, the field of blood group typing is undergoing a pragmatic evolution characterized by greater automation, expanded molecular capabilities, and an elevated focus on supply chain resilience and interoperability. Clinical imperatives for transfusion safety, newborn screening, and reliable donor screening continue to drive demand for solutions that are clinically validated, operationally sustainable, and supported by strong service frameworks. As laboratories and blood services navigate tariff changes, regulatory complexity, and technological choice, the organizations that emphasize validated integration, supplier reliability, and adaptive procurement will be best positioned to deliver consistent patient-centered outcomes.

Moving forward, continued collaboration between diagnostic manufacturers, reagent suppliers, software integrators, and clinical stakeholders will be essential to translate innovation into routine practice. By aligning investments with clinical workflow realities and regulatory expectations, stakeholders can ensure that technological advances not only improve diagnostic precision but also enhance the efficiency and safety of transfusion services and related clinical programs.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of next-generation sequencing-based blood group genotyping platforms for enhanced transfusion safety and compatibility testing
• 5.2. Growth in point-of-care blood typing devices integrating AI-driven analysis in emergency and critical care settings
• 5.3. Rising investment in microarray-based high-throughput blood antigen screening technologies for optimal donor-recipient matching
• 5.4. Emergence of smartphone-enabled hemagglutination assays for decentralized blood group typing in remote healthcare facilities
• 5.5. Regulatory push for non-invasive fetal RhD genotyping through cell-free DNA testing platforms to reduce alloimmunization risk
• 5.6. Integration of blockchain technology for secure and traceable blood type data management across hospital and transfusion networks
• 5.7. Shift toward automation with fully integrated sample-to-result blood group analyzers in high-volume clinical laboratories

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Group Typing Market, by Product Type

• 8.1. Instruments
  • 8.1.1. Automated Blood Typers
  • 8.1.2. Gel Card Analyzers
• 8.2. Reagents
  • 8.2.1. Antisera Reagents
  • 8.2.2. Reagent Red Blood Cells
  • 8.2.3. Screening Cells
• 8.3. Software & Services
  • 8.3.1. LIS Integration
  • 8.3.2. Support & Maintenance

9. Blood Group Typing Market, by Technology

• 9.1. Flow Cytometry
• 9.2. Gel Centrifugation
• 9.3. Microplate Agglutination
• 9.4. PCR
  • 9.4.1. Digital PCR
  • 9.4.2. Real-Time PCR

10. Blood Group Typing Market, by End User

• 10.1. Blood Banks
  • 10.1.1. Government Blood Banks
  • 10.1.2. Private Blood Banks
• 10.2. Clinical Laboratories
  • 10.2.1. Hospital Based Laboratories
  • 10.2.2. Independent Laboratories
• 10.3. Hospitals & Diagnostic Centers
  • 10.3.1. Private Hospitals
  • 10.3.2. Public Hospitals

11. Blood Group Typing Market, by Application

• 11.1. Donor Screening
  • 11.1.1. Blood Typing
  • 11.1.2. Infectious Disease Screening
• 11.2. Newborn Screening
• 11.3. Pretransfusion Testing

12. Blood Group Typing Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Blood Group Typing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Blood Group Typing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Ortho Clinical Diagnostics, Inc.
  • 15.3.2. Abbott Laboratories
  • 15.3.3. Thermo Fisher Scientific Inc.
  • 15.3.4. Grifols, S.A.
  • 15.3.5. Bio-Rad Laboratories, Inc.
  • 15.3.6. Immucor, Inc.
  • 15.3.7. Sysmex Corporation
  • 15.3.8. BioMerieux SA
  • 15.3.9. Quotient Limited
  • 15.3.10. Fujirebio Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL BLOOD GROUP TYPING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BLOOD GROUP TYPING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. BLOOD GROUP TYPING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BLOOD GROUP TYPING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BLOOD GROUP TYPING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BLOOD GROUP TYPING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 235. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
• TABLE 236. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
• TABLE 251. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
• TABLE 254. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
• TABLE 257. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
• TABLE 258. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
• TABLE 259. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 260. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 261. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
• TABLE 262. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
• TABLE 271. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
• TABLE 272. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
• TABLE 273. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 274. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 275. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
• TABLE 276. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
• TABLE 277. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 279. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
• TABLE 280. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
• TABLE 281. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
• TABLE 282. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
• TABLE 283. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
• TABLE 284. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
• TABLE 285. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 286. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 287. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
• TABLE 288. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 313. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
• TABLE 314. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
• TABLE 315. EUROPE BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 316. EUROPE BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 317. EUROPE BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 318. EUROPE BLOO